Health Press Release – Newsletter for November 18, 2010

Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients

MONT-SAINT-GUIBERT, Belgium, November 17, 2010 – The Belgian biotechnology company, Cardio3 BioSciences – a
leader in discovery and development of regenerative and protective therapies
for the treatment of cardiovascular diseases – today announces positive
six-month results, including significant functional and clinical benefit,
from the Phase II clinical trial of its development programme C-Cure(R),
designed as a novel stem cell … Read this article on Gaea Times at : Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients.

Mollie’s Fund Launches App for Skin Cancer Awareness

GARDEN CITY, New York, November 17, 2010 – The Mollie Biggane Melanoma Foundation, www.molliesfund.org has
announced the launch of a free application that will provide valuable
information for skin cancer and melanoma detection. This free application is
available on iPhone, iPod Touch and the iPad. It can also be downloaded
through iTunes.

Mollie's Fund, with …. Source article  : Mollie's Fund Launches App for Skin Cancer Awareness.

Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session

A Second AHA Presentation Includes Mouse Model Data Showing Plaque Reduction.

CHICAGO, November 17, 2010 – Resverlogix Corp. ("Resverlogix") (TSX:RVX) announces its top line
results of the ASSERT Phase 2 clinical trial which will be highlighted at the
prestigious American Heart Association Scientific Sessions 2010 Late Breaking
Clinical Trial session, by principal investigator Dr. Stephen Nicholls of the
Cleveland … Read this article on Gaea Times at : Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session.